About Galectin Therapeutics Inc.
https://galectintherapeutics.comGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases.
CEO
Joel Lewis CPA
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2012-03-23 | Reverse | 1:6 |
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:2.25M
Value:$6.74M
BLACKROCK INC.
Shares:1.56M
Value:$4.69M
ADVISOR GROUP HOLDINGS, INC.
Shares:1.22M
Value:$3.67M
Summary
Showing Top 3 of 106
About Galectin Therapeutics Inc.
https://galectintherapeutics.comGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $4.2M ▼ | $-8.18M ▼ | 0% | $-0.13 ▼ | $-6.36M ▼ |
| Q2-2025 | $0 | $4.62M ▼ | $-7.52M ▲ | 0% | $-0.12 ▲ | $-5.69M ▲ |
| Q1-2025 | $0 | $7.89M ▼ | $-9.63M ▲ | 0% | $-0.15 ▲ | $-7.88M ▲ |
| Q4-2024 | $0 | $12.42M ▲ | $-11.97M ▼ | 0% | $-0.19 ▼ | $-10.23M ▼ |
| Q3-2024 | $0 | $9.06M | $-11.22M | 0% | $-0.18 | $-9.72M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $11.53M ▼ | $12.87M ▼ | $138.17M ▲ | $-125.3M ▼ |
| Q2-2025 | $13.77M ▲ | $15.6M ▲ | $132.77M ▲ | $-117.17M ▼ |
| Q1-2025 | $7.43M ▼ | $9.53M ▼ | $121.79M ▲ | $-112.26M ▼ |
| Q4-2024 | $15.12M ▼ | $17.5M ▼ | $120.56M ▼ | $-103.07M ▼ |
| Q3-2024 | $27.06M | $28.97M | $121.45M | $-92.48M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-8.18M ▼ | $-3.54M ▲ | $0 | $1.3M ▼ | $-2.25M ▼ | $-3.54M ▲ |
| Q2-2025 | $-7.52M ▲ | $-6.6M ▲ | $0 | $12.94M ▲ | $6.34M ▲ | $-6.6M ▲ |
| Q1-2025 | $-9.63M ▲ | $-7.69M ▲ | $0 | $0 ▼ | $-7.69M ▲ | $-7.69M ▲ |
| Q4-2024 | $-11.97M ▼ | $-12.79M ▼ | $0 | $851K ▼ | $-11.94M ▼ | $-12.79M ▼ |
| Q3-2024 | $-11.22M | $-8.54M | $0 | $10M | $1.46M | $-8.54M |
CEO
Joel Lewis CPA
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2012-03-23 | Reverse | 1:6 |
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:2.25M
Value:$6.74M
BLACKROCK INC.
Shares:1.56M
Value:$4.69M
ADVISOR GROUP HOLDINGS, INC.
Shares:1.22M
Value:$3.67M
Summary
Showing Top 3 of 106